Abstract. The aim of this paper is to descript the impact factors of HIV/AIDS patients' quality of life (QOL) after antiretroviral therapy by reviewing cohort studies. We searched PubMed and EmBase databases from inception to September 2015 for primary cohort studies about HIV/AIDS patients' QOL. Thirty cohort studies were enrolled in this review. Among the predictors, job stability and social support were mentioned as associating positively with QOL. IDU, symptoms, depressions, and higher viral loads associated negatively with QOL. The studies did not all achieve the same results, but none of the studies directly contradicted each other. To improve HAART benefits for HIV/AIDS patients, it is important to improve QOL predictors and weaken factors associated with decreased QOL, especially for female and older HIV/AIDS patients.
Introduction
UNAIDS reported that 35 million Human Immunodeficiency Virus (HIV) infectors by the end of 2013 [1] . Highly active antiretroviral therapy (HAART) has increased the survival rates of HIV/AIDS patients [2] . The clinical success of HAART has turned HIV/AIDS from a fatal disease to a controlled one. However, survivors still suffer from quality of life (QOL) concerns due to complex regimens and adverse effects associated with antiretroviral drugs [3] . Thus, with the availability of more efficient and less toxic regimens, maximizing QOL has become a priority for managing HIV/AIDS [4] .
QOL is a multidimensional construct that includes global health perspectives, functional status, biological and physical variables, individual and environmental characteristics, and general perceptions. The World Health Organization (WHO) QOL Group defines QOL as "an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns" [5] . Various scales have been developed to measure QOL, including medical outcomes and survey short forms (MOS SF), the Karnofsky Performance Scale Index (KPSI), and the EuroQol standard scale (EQ-5D). Some also include patient-specific measurements, such as functional assessment of HIV infection (FAHI), MOS-HIV, and WHOQOL-HIV. These scales are thought to be reliable and valid and are widely used for measuring QOL worldwide [6] .
Many QOL studies have been conducted on HIV/AIDS since HAART's introduction; they found that HAART could improve QOL [7] . High QOL could encourage the patient to continue HAART treatment, thus improving HAART benefits. Tracking QOL could improve the QOL of HIV/AIDS patients. Unfortunately, QOL impact factors for HIV/AIDS patients are not consistent. Cohort studies could assess the causal effects of socio-demographics and clinical factors on QOL. Therefore, we reviewed cohort studies reporting the QOL of HIV/AIDS patients with HAART to better understand the impact factors on subjects' QOL.
Methods

Search Strategy
The terms "Acquired Immunodeficiency Syndrome", "Human Immunodeficiency Virus", "quality of life", and "antiretroviral" were searched in articles in the PubMed and EmBase databases from inception to September 2015. The references cited by the retrieved articles that satisfied the enrollment criteria were taken as a supplementary search.
Study Selection
Two reviewers independently screened the title/abstract of each retrieved article to find qualifying studies, and then reviewed the full text of qualifying studies (LZ, JG). Papers were excluded if the title/abstract showed that the study was not about HIV/AIDS, did not mention antiretroviral therapy, did not clearly present QOL data, was a study of children, or was a review study. Papers were included if the full text showed that the study was a cohort study, the patients had taken ART; the study analyzed QOL, and restrictions were not placed on publication dates or location.
Methodological Quality Assessment
Two reviewers independently assessed the quality of the manuscripts included in this study by a 14-item checklist that was modified according to the recommendations of the meta-analysis of Observational Studies in Epidemiology Group guidelines [8] . Each study scored one point for each matching criteria. Higher scores (maximum 14) indicated higher qualities for the studies. Studies that scored ≥ 10 points were taken as high quality, 6-9 were taken as moderate quality, and < 6 points were taken as low quality. The criteria were as follows: a) Explain how the study size was determined; b) Formulated inclusion and/or exclusion criteria; c) Response rate was >75%; d) No selection bias between response and non-response; e) Described the data collection process; f) Informed consent form was signed; g) Clearly described statistical methods; h) QOL scale used was standardized or validated; i) Follow-up rate was >80%; j) No difference between follow-up and no follow-up; k) Clearly described the socio-demographic data; l)Clearly described the clinical data; m) Described adherence; n) Outcome with multiple analyses.
Data Extraction and Statistic
Data from the studies included in this review extracted by two researchers independently were as the follows: name of the first author, study location, publication' year, scales used to measure QOL, follow-up period, sample size, age, gender, disease characteristics such as disease stage, CD4 T lymphocyte cells counts, viral loads, and post-HAART QOL predictors. If there were discrepancies between the two reviewers, a third reviewer specializing in it was resorted to resolve.
The data was not synthesized due to the differences QOL scales used and the indexes measured the changes of QOL in the studies. We only qualitative description the impact factors were positively or negatively with QOL.
Results
Included Studies
1648 PubMed abstracts and 1,463 EMBASE abstracts were extracted; 2,361 potentially relevant citations were identified. 2,171 articles were excluded after reviewing the title and abstracts; no articles that met the inclusion criteria were included in the supplementary citation searches. At last, 13 primary studies were included in this review (Figure 1 ). 
Quality of Included Studies
The scores of all the included studies were between 7 and 11 points. Three studies were taken as high quality, and others were moderate quality. All studies used a standardized QOL scale and clearly described statistical methods, but only one study explained how the study size was arrived at. Table 1 presents the quality assessment of the studies. Table 1 . Quality assessment of individual cohort studies included in this study. 
Characteristics of Included Studies
The earliest included study was published in 2003, the latest in 2015. Three studies were located in France, three in United States, five in Africa, one in Brazil, and one in China. Sample sizes varied from 197 to 1000 patients. One study lasted 4 months, one last 6 months, and others lasted more than 12 months. Six QOL scales were used in the included studies and they were MOS SF-21, EQ-5D, MOS SF-36, WHOQOL-HIV, HAT-QOL, and MOS-HIV. Table 2 presents the characteristics of the included studies. 
Predictors Associated with QOL of HIV/AIDS Patients
One study only analyzed adherence associated with the QOL, and one study analyzed the HAART duration and associated adverse effects, while another analyzed more than five associated predictors. Last-visit QOL scores were analyzed in seven of the studies [9, 12, 13, [16] [17] [18] 20] ; the ratio of good/normal QOL at the last visit was analyzed in two studies [14, 21] , and QOL change was analyzed in four studies [10, 11, 15, 19] . Among the predictors, job stability and social support associated positively with QOL. IDU, symptoms, depression, and higher viral loads associated negatively with QOL. Some studies indicated that older patients had poorer QOL; other studies did not report this association. Some studies indicated that females were more likely to experience lower QOL; others did not report this association. Some studies indicated that living with a spouse, higher education, higher monthly incomes, higher adherence, and higher CD4 cell counts, and higher baseline QOL associated positively with QOL; others did not report this association. Table 3 presents predictors associated with QOL. 
Discussion
HIV/AIDS patients need to submit to HAART treatment for a long period of time to maximize effectiveness. Because HIV/AIDS is a chronic disease, the therapy aims to prolong the life-span and improve QOL. This study establishes predictors, effects on QOL, and the extent to which an improvement in the patient-provider relationship improves patients' QOL. In this analysis, most predictors were not consistent; however, predictors did not directly contradict each other (ie, the same predictor was not shown to positively associate and negatively associate with QOL across multiple studies). Of the predictors, job stability and social support positively associated with the QOL of HIV/AIDS patients; meanwhile, IDU, more symptoms, depression, and higher viral loads negatively associated with QOL. Age negatively associated with QOL in five studies; in these, the QOL score at the last visit was analyzed. Age-related physiological changes with older HIV/AIDS patients introduced more non-AIDS defining illnesses, including cardiovascular disease, liver disease, renal impairment, and malignancy [22] . Antoine et al reported that age was not associated with QOL score changes, but older subjects generally had lower QOL scores at the beginning of the study [11] . In the Brazil and France studies, being female was negatively associated with QOL; this was not the case other studies. Some investigators have suggested that gender-based QOL differences stem from psychological illnesses and physical factors, such as fat composition, hormonal effects on drug metabolism, etc. [23] [24] [25] . Additionally, environmental and cultural factors may account for this gender-based discrepancy.
The studies did not all agree as to whether or not living with a spouse, higher education, and increased income has an effect on QOL; these factors were found to have a positive association or no association with QOL. Some studies indicated that HIV/AIDS patients with more education gained more knowledge about HIV/AIDS to adjust their living situation; higher income patients would have improved material lives [20] . In other words, patients with higher monthly incomes had more financial flexibility, which enabled them to adapt to the life-altering disease [14, 18] . Clinical characteristics negatively associated with QOL included more symptoms, adverse effects, lower CD4 cell counts, and higher viral loads.
This review has some limitations. Measuring QOL is somewhat subjective, and the different scales in the studies of this review were used to measure it, therefore, the results can't be merged by forest plots. Additionally, no standard exists to assess QOL-related study quality [26] . The type of HAART was complex and could cause more side effects could affect QOL, but the type of HAART used in the studies included was not described. The longest follow-up time of the included studies was 24 months, so maybe the QOL change was too little to observe the effector. In summary, the QOL of HIV/AIDS patients were affected by many factors. The studies did not find identical results on some factors associated with QOL, but the studies did not directly contradict each other. To enhance HAART benefits for HIV/AIDS patients, we need to understand predictors associated with QOL, especially for female and older HIV/AIDS patients.
